Which has stronger earnings & valuation, ORIC or NKTX?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is ORIC or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Nkarta N/A -30.90% -24.20%

Which has higher valuation and earnings, SANA or NKTX?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is SANA or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Nkarta N/A -30.90% -24.20%

Which has preferable valuation and earnings, PHAR or NKTX?

Pharming Group has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $376.13M 2.40 $2.85M $0.16 80.00 Nkarta N/A N/A -$104.08M -$1.34 N/A

Is PHAR or NKTX more profitable?

Pharming Group has a net margin of 3.30% compared to Nkarta's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Pharming Group 3.30% 4.64% 2.55% Nkarta N/A -30.90% -24.20%

Is NKTX or KURA more profitable?

Nkarta has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Nkarta's return on equity of -30.90% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Kura Oncology -411.19% -141.95% -43.28%

Is ABUS or NKTX more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to Nkarta's net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% Nkarta N/A -30.90% -24.20%

Nkarta (NKTX) Competitors

$2.40 -0.11 (-4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.44 +0.04 (+1.54%)

As of 07:10 PM Eastern

Compare

NKTX vs. ORIC, SANA, PHAR, KURA, and ABUS

Should you buy Nkarta stock or one of its competitors? MarketBeat compares Nkarta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nkarta include Oric Pharmaceuticals (ORIC), Sana Biotechnology (SANA), Pharming Group (PHAR), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Nkarta compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Nkarta. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 0 mentions for Nkarta. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Nkarta'saverage media sentiment score.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Nkarta	Neutral

Nkarta's return on equity of -30.90% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Nkarta	N/A	-30.90%	-24.20%

Oric Pharmaceuticals presently has a consensus price target of $19.36, suggesting a potential upside of 157.15%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 347.92%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Nkarta beats Oric Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Nkarta compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Sana Biotechnology is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

In the previous week, Sana Biotechnology had 4 more articles in the media than Nkarta. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Nkarta. Sana Biotechnology's average media sentiment score of 0.19 beat Nkarta's score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Nkarta	Neutral

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sana Biotechnology currently has a consensus target price of $9.50, indicating a potential upside of 253.16%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 347.92%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nkarta's return on equity of -30.90% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Nkarta	N/A	-30.90%	-24.20%

Summary

Sana Biotechnology and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

How does Nkarta compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Pharming Group has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.40	$2.85M	$0.16	80.00
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Pharming Group has a net margin of 3.30% compared to Nkarta's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Nkarta	N/A	-30.90%	-24.20%

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pharming Group presently has a consensus target price of $38.33, suggesting a potential upside of 199.48%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 347.92%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Pharming Group had 3 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Pharming Group and 0 mentions for Nkarta. Pharming Group's average media sentiment score of 0.66 beat Nkarta's score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Positive
Nkarta	Neutral

Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Pharming Group beats Nkarta on 9 of the 15 factors compared between the two stocks.

How does Nkarta compare to Kura Oncology?

Nkarta (NASDAQ:NKTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

In the previous week, Kura Oncology had 13 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Kura Oncology and 0 mentions for Nkarta. Nkarta's average media sentiment score of 0.00 beat Kura Oncology's score of -0.15 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Neutral
Kura Oncology	Neutral

Nkarta has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Kura Oncology	$71.64M	10.61	-$278.67M	-$3.35	N/A

Nkarta has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

80.5% of Nkarta shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nkarta has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Nkarta's return on equity of -30.90% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Kura Oncology	-411.19%	-141.95%	-43.28%

Nkarta currently has a consensus target price of $10.75, indicating a potential upside of 347.92%. Kura Oncology has a consensus target price of $25.58, indicating a potential upside of 198.87%. Given Nkarta's stronger consensus rating and higher probable upside, equities analysts plainly believe Nkarta is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Nkarta beats Kura Oncology on 13 of the 16 factors compared between the two stocks.

How does Nkarta compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 17.92%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 347.92%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Arbutus Biopharma has a net margin of 83.95% compared to Nkarta's net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Nkarta	N/A	-30.90%	-24.20%

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$191.45M	4.37	-$33.50M	$0.83	5.11
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Arbutus Biopharma's average media sentiment score of 0.00 equaled Nkarta'saverage media sentiment score.

Company	Overall Sentiment
Arbutus Biopharma	Neutral
Nkarta	Neutral

Arbutus Biopharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

Arbutus Biopharma beats Nkarta on 8 of the 14 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.71M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-1.79	18.93	23.75	23.75
Price / Sales	N/A	176.74	480.27	84.51
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.55	8.04	10.28	6.78
Net Income	-$104.08M	$23.89M	$3.57B	$337.51M
7 Day Performance	-23.57%	-5.97%	-1.43%	-2.72%
1 Month Performance	-24.76%	2.78%	3.27%	1.87%
1 Year Performance	26.32%	36.26%	23.37%	26.61%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	3.1032 of 5 stars	$2.40 -4.4%	$10.75 +347.9%	+32.1%	$171.71M	N/A	N/A	140
ORIC Oric Pharmaceuticals	1.9827 of 5 stars	$8.98 +6.3%	$19.36 +115.6%	-19.5%	$929.59M	N/A	N/A	80	Analyst Forecast High Trading Volume
SANA Sana Biotechnology	3.4539 of 5 stars	$3.21 -2.7%	$9.50 +196.0%	-5.6%	$918.36M	N/A	N/A	380	Analyst Downgrade Gap Up
PHAR Pharming Group	3.9049 of 5 stars	$13.10 +0.8%	$38.33 +192.6%	+5.6%	$917.42M	$376.13M	81.88	280
KURA Kura Oncology	2.1755 of 5 stars	$9.03 -11.5%	$25.90 +186.8%	+29.9%	$905.50M	$71.64M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Nkarta compare to Oric Pharmaceuticals?

Summary

How does Nkarta compare to Sana Biotechnology?

Summary

How does Nkarta compare to Pharming Group?

Summary

How does Nkarta compare to Kura Oncology?

Summary

How does Nkarta compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Nkarta compare to Oric Pharmaceuticals?

Which has more volatility & risk, ORIC or NKTX?

Do insiders and institutionals have more ownership in ORIC or NKTX?

Which has stronger earnings & valuation, ORIC or NKTX?

Does the media favor ORIC or NKTX?

Is ORIC or NKTX more profitable?

Do analysts prefer ORIC or NKTX?

Summary

How does Nkarta compare to Sana Biotechnology?

Which has higher valuation and earnings, SANA or NKTX?

Which has more risk & volatility, SANA or NKTX?

Does the media favor SANA or NKTX?

Do insiders and institutionals have more ownership in SANA or NKTX?

Do analysts rate SANA or NKTX?

Is SANA or NKTX more profitable?

Summary

How does Nkarta compare to Pharming Group?

Which has preferable valuation and earnings, PHAR or NKTX?

Is PHAR or NKTX more profitable?

Do insiders & institutionals believe in PHAR or NKTX?

Do analysts rate PHAR or NKTX?

Does the media favor PHAR or NKTX?

Which has more risk and volatility, PHAR or NKTX?

Summary

How does Nkarta compare to Kura Oncology?

Does the media favor NKTX or KURA?

Which has preferable valuation and earnings, NKTX or KURA?

Which has more volatility & risk, NKTX or KURA?

Do institutionals and insiders have more ownership in NKTX or KURA?

Is NKTX or KURA more profitable?

Do analysts prefer NKTX or KURA?

Summary

How does Nkarta compare to Arbutus Biopharma?

Do analysts rate ABUS or NKTX?

Is ABUS or NKTX more profitable?

Do institutionals and insiders have more ownership in ABUS or NKTX?

Which has better valuation & earnings, ABUS or NKTX?

Does the media refer more to ABUS or NKTX?

Which has more risk & volatility, ABUS or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools